LivaNova - LIVN Stock Forecast, Price & News

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

LivaNova Stock Up 2.4 %

NASDAQ:LIVN traded up $1.45 during trading on Wednesday, hitting $62.37. The stock had a trading volume of 2,700 shares, compared to its average volume of 346,909. LivaNova has a 12 month low of $56.13 and a 12 month high of $93.89. The company has a market capitalization of $3.33 billion, a PE ratio of -110.66 and a beta of 0.89. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.47 and a current ratio of 2.93. The company's 50-day moving average price is $62.87 and its two-hundred day moving average price is $70.84.

LivaNova (NASDAQ:LIVN - Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.51 by $0.02. LivaNova had a positive return on equity of 9.35% and a negative net margin of 2.74%. The company had revenue of $254.20 million for the quarter, compared to analysts' expectations of $249.55 million. During the same quarter in the prior year, the business posted $0.52 EPS. The business's revenue was down 3.9% compared to the same quarter last year. As a group, sell-side analysts forecast that LivaNova will post 2.4 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Needham & Company LLC decreased their target price on LivaNova from $106.00 to $88.00 and set a "buy" rating for the company in a research report on Thursday, August 4th. StockNews.com upgraded LivaNova from a "hold" rating to a "buy" rating in a research report on Wednesday, August 3rd. Finally, Piper Sandler decreased their price objective on LivaNova from $104.00 to $99.00 in a research report on Thursday, May 5th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $98.50.